The first reverse split got the stock uplisted to Nasdaq. It wasn’t done to avoid a delisting as is more common in the biotech space. There is no reason for another reverse split as things stand now.
I would only agree with this statement if PISCES trial is a failure next year..... I don't believe it will fail though....and we will have a much much higher valuation.